Skip to main content

Table 1 Clinical assessment and neuroimaging at baseline and follow-up

From: MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial

Baseline

 

Clinical assessment

Demographics, risk factors, medication, medical history, NIHSS

Neuro-imaging

Unenhanced CT and CT angiography*

Follow-up

 

Clinical assessment at 24 hours

NIHSS. Adverse events.

Neuro-imaging at 24 hours

CT angiography*

Neuro-imaging at 5-7 days

Unenhanced CT or MRI

Clinical assessment at 1 week or discharge

NIHSS; Barthel index

Clinical assessment at 90 days

Modified Rankin score, Barthel index, EQ5D

  1. *Magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) are allowed; computed tomography (CT) perfusion is recommended but not obligatory. EQ-5D, EuroQol 5D measurement tool for health-related quality of life; NIHSS, National Institutes of Health stroke scale.